ClinicalTrials.gg

Macular Degeneration clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,460 studies for Macular Degeneration across more than 10 countries. 237 are recruiting or about to start. 1,132 of them are mainly about Macular Degeneration (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 4 narrower conditions too, such as Macular Edema: 2,308 studies, 336 open.

ClinicalTrials.gov finds 2,178 studies for Macular Degeneration. How that becomes 1,460 here

This page counts the studies the registry files under Macular Degeneration, and those it files under no condition that list Macular Degenerationthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 17, 2026. How condition pages count

  1. 2,178Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −525Filed under a narrower condition, counted on its own pageMacular Edema 376 · Geographic Atrophy 62 · Stargardt Disease 47 · Wet Macular Degeneration 37
  3. −81List Macular Degeneration as a condition, but the registry did not file them under itMost often written as “Neovascular Age-related Macular Degeneration” (15), “Diabetic Maculopathy” (9), and “Neovascular Age-related Macular Degeneration (nAMD)” (6). The registry filed 10 of them under no condition at all, and the others under other conditions only, most often Retinal Vein Occlusion (15) and Choroidal Neovascularization (8).
  4. −112Match it another way59 name it in the title, 9 in a keyword, and 44 by a synonym or other text the search reads.
  5. 1,460The count on this page286 of them list Macular Degeneration in their own words; the registry filed them under no condition.

Status

Completed
823
Recruiting
166
Status unknown
161
Terminated
123
Active, not recruiting
68
Not yet recruiting
61

Phase

Phase 2
348
Phase 1
243
Phase 3
209
Phase 4
105
Early Phase 1
14

Where

United States
645
France
120
Germany
110
United Kingdom
108
China
106
Italy
97

Who develops what

Add Macular Degeneration to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 55 programs from 44 companies, 41 with this as their studies’ main aim; 15 with a live phase 3 study; 16 primary completions in the next 12 months. Compare Hoffmann-La Roche, AbbVie and Astellas Pharma here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
afliberceptRecent, repeated
Evidence
  • NCT07816315 · Ollin Biosciences, Inc. · Phase 3 · live · comparator · “Aflibercept” · registered Sep 2026
  • NCT07798375 · Everest Medicines (China) Co.,Ltd. · Phase 2 · live · comparator · “Aflibercept (Eylea)” · registered Aug 2026
  • NCT07614776 · amgen · Phase 3 · live · comparator · “Aflibercept (US) 8 mg” · registered May 2026
  • NCT07557121 · AiViva BioPharma, Inc. · Phase 2 · live · comparator · “EYLEA® (aflibercept) Injection 2 mg (0.05mL)” · registered Apr 2026
  • NCT07496567 · Merck & Co., Inc · Phase 3 · live · comparator · “Aflibercept” · registered Mar 2026
Regeneron Pharmaceuticals28% of its industry studiesUS: Regeneron Pharmaceuticals (FDA 2011) + 5 othersEU: Bayer (EMA 2012) + 12 others2127 studies
RanibizumabRecent, repeated
Evidence
  • NCT07816289 · Ollin Biosciences, Inc. · Phase 3 · live · comparator · “Ranibizumab” · registered Sep 2026
  • NCT06305416 · incepta pharmaceuticals ltd · Phase 3 · comparator · “Lucentis” · registered Mar 2024
  • NCT06190093 · outlook therapeutics inc · Phase 3 · comparator · “ranibizumab” · registered Dec 2023
  • NCT05571267 · Astellas Pharma Inc · Phase 2 · background · “Lucentis” · registered Sep 2022
  • NCT05480293 · Sinocelltech Group Limited · Phase 3 · live · comparator · “Ranibizumab” · registered Jul 2022
Novartis52% of its industry studiesUS: Hoffmann-La Roche (FDA 2006) + 3 othersEU: Novartis (EMA 2007) + 9 others88 studies

9 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
QL1207H☆ Track1 live phase-3 study: NCT07489586Qilu Pharmaceutical Co., Ltd.
AxitinibApproved: US 2012 · EU☆ Track3 live phase-3 studies: NCT07516132, NCT06495918, NCT06223958Ocular Therapeutix, Inc.
RanibizumabApproved: US 2006 · EU 2007☆ Track3 live phase-3 studies: NCT06847542, NCT04657289, NCT05562947Hoffmann-La Roche
IBI302☆ Track1 live phase-3 study: NCT05972473Innovent Biologics, Inc.
QA108☆ Track1 live phase-3 study: NCT07189169Smilebiotek Zhuhai Limited

The 5 in phase 3 with the nearest primary completion, of 55 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (16)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.QL1207H · Qilu Pharmaceutical Co., Ltd. · Phase 3 main aim+ QL1207H vs afliberceptNCT07489586 A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration — primary endpoint: Change from baseline in BCVA at Week 12 · 356 enrolled
  • 8 Jan 2027 est.Axitinib · Ocular Therapeutix, Inc. · Phase 3 main aimvs afliberceptNCT06495918 Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration — primary endpoint: Best Corrected Visual Acuity (BCVA) · 825 enrolled
  • 4 Feb 2027 est.Ranibizumab · Hoffmann-La Roche · Phase 3 main aimNCT04657289 A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) — primary endpoint: Change from baseline in Best-corrected visual acuity (BCVA) score averaged over Weeks 68 and 72, as assessed using the ETDRS chart starting at a distance of 4 meters · 451 enrolled

13 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Macular Degeneration studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Angiogenesis inhibitors 7 open · Tyrosine kinase inhibitors (TKIs) 1 open · Local anesthetics 1 open · Corticosteroids 24 · mTOR inhibitors 7

Coming up

83studies finish main data collection within a year13 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger. 19 (11%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 35 (21%) take healthy volunteers.

Recruiting studies that take each age, of 166
AgeWomenMen
1015 (9%)15 (9%)
1852 (31%)52 (31%)
3056 (34%)56 (34%)
4058 (35%)58 (35%)
50132 (80%)132 (80%)
65163 (98%)163 (98%)
75162 (98%)162 (98%)
85153 (92%)153 (92%)

Across all 1,460 studies, recruiting or not: 3% stop at 75 or younger and 2% at 65; 8% take children; <1% are for women only and <1% for men only; 17% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Macular Degeneration studies take

Of 83 phase 2 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 118 mo10–30 · 75 studies15 mo9–27 · 60 studies—
Phase 1/232 mo18–65 · 52 studies——
Phase 224 mo16–35 · 83 studies22 mo15–30 · 66 studies—
Phase 324 mo20–35 · 83 studies24 mo20–33 · 77 studies—
Phase 426 mo14–39 · 45 studies27 mo19–36 · 24 studies—
Interventional, no phase37 mo17–60 · 133 studies—41 mo17–56 · 105 studies
Observational45 mo15–77 · 162 studies42 mo14–69 · 56 studies48 mo18–98 · 106 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,460. Browse all 1,460 → or search them.